Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection

Vaccines

Volumn 4, Issue 3, 2016, Pages

  Swadling, Leo ^a   Halliday, John ^a,b,c   Kelly, Christabel ^a,b   Brown, Anthony ^a   Capone, Stefania ^d   Ansari, M Azim ^a   Bonsall, David ^a   Richardson, Rachel ^a   Hartnell, Felicity ^a   Collier, Jane ^b   Ammendola, Virginia ^d   Del Sorbo, Mariarosaria ^d   Von Delft, Annette ^a   Traboni, Cinzia ^d   Hill, Adrian V S ^a,e   Colloca, Stefano ^d   Nicosia, Alfredo ^d,f,g   Cortese, Riccardo ^h   Klenerman, Paul ^a,b,e   Folgori, Antonella ^d   Barnes, Eleanor ^a,b,e   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d Reithera Srl ^*  (Italy)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Keires AG   (Switzerland)

Author keywords

Adenovirus; Exhaustion; HCV; Immunotherapy; Modified vaccinia Ankara; T cells; Therapeutic vaccination

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; GRANZYME B; HEPATITIS C VACCINE; PEGINTERFERON ALPHA; RIBAVIRIN; TUMOR NECROSIS FACTOR; VACCINE;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CROSS REACTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOGENICITY; MALE; MIDDLE AGED; PHENOTYPE; PRE T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION;

EID: 85016898334     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines4030027     Document Type: Article

References (68)

1. Messina, J.P.; Messina, I.X.; Flaxman, A.; Brown, A.; Cooke, G.S.; Pybus, O.G.; Barnes, E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015, 61, 77–87. [CrossRef] [PubMed]
2. Kohli, A.; Shaffer, A.; Sherman, A.; Kottilil, S. Treatment of hepatitis C: A systematic review. JAMA 2014, 312, 631–640. [CrossRef] [PubMed]
3. Walker, C.M.; Grakoui, A. Hepatitis C virus: Why do we need a vaccine to prevent a curable persistent infection? Curr. Opin. Immunol. 2015, 35, 137–143. [CrossRef] [PubMed]
4. Martin, N.K.; Foster, G.R.; Vilar, J.; Ryder, S.; Cramp, M.E.; Gordon, F.; Dillon, J.F.; Craine, N.; Busse, H.; Clements, A.; et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: Real world results and modelling of treatment impact. J. Viral Hepat. 2015, 22, 399–408. [CrossRef] [PubMed]
5. Dutta, A.; Barker, C.; Kallarakal, A. The HIV treatment gap: Estimates of the financial resources needed versus available for scale-up of antiretroviral therapy in 97 countries from 2015 to 2020. PLoS Med. 2015, 12, e1001907. [CrossRef] [PubMed]
6. Grady, B.P.; Schinkel, J.; Thomas, X.V.; Dalgard, O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin. Infect. Dis. 2013, 57, S105–S110. [CrossRef] [PubMed]
7. Aspinall, E.J.; Corson, S.; Doyle, J.S.; Grebely, J.; Hutchinson, S.J.; Dore, G.J.; Goldberg, D.J.; Hellard, M.E. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clin. Infect. Dis. 2013, 57, S80–S89. [CrossRef] [PubMed]
8. Osburn, W.O.; Fisher, B.E.; Dowd, K.A.; Urban, G.; Liu, L.; Ray, S.C.; Thomas, D.L.; Cox, A.L. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010, 138, 315–324. [CrossRef] [PubMed]
9. Dahari, H.; Feinstone, S.M.; Major, M.E. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010, 139, 965–974. [CrossRef] [PubMed]
10. Mehta, S.H.; Cox, A.; Hoover, D.R.; Wang, X.-H.; Mao, Q.; Ray, S.; Strathdee, S.A.; Vlahov, D.; Thomas, D.L. Protection against persistence of hepatitis C. Lancet 2002, 359, 1478–1483. [CrossRef]
11. Ishii, S.; Koziel, M.J. Immune responses during acute and chronic infection with hepatitis C virus. Clin. Immunol. 2008, 128, 133–147. [CrossRef] [PubMed]
12. Rehermann, B. Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence. J. Clin. Investig. 2009, 119, 1745–1754. [CrossRef] [PubMed]
13. Bowen, D.G.; Walker, C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436, 946–952. [CrossRef] [PubMed]
14. Klenerman, P.; Thimme, R. T cell responses in hepatitis C: The good, the bad and the unconventional. Gut 2012, 61, 1226–1234. [CrossRef] [PubMed]
15. Swadling, L.; Klenerman, P.; Barnes, E. Ever closer to a prophylactic vaccine for HCV. Expert Opin. Biol. Ther. 2013, 13, 1109–1124. [CrossRef] [PubMed]
16. Halliday, J.; Klenerman, P.; Barnes, E. Vaccination for hepatitis C virus: Closing in on an evasive target. Expert Rev. Vaccines 2011, 10, 659–672. [CrossRef] [PubMed]
17. Klade, C.S.; Schuller, E.; Boehm, T.; von Gabain, A.; Manns, M.P. Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine 2012, 30, 2943–2950. [CrossRef] [PubMed]
18. Habersetzer, F.; Baumert, T.F.; Stoll-Keller, F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr. Opin. Mol. Ther. 2009, 11, 456–462. [PubMed]
19. Gowans, E.J.; Roberts, S.; Jones, K.; Dinatale, I.; Latour, P.A.; Chua, B.; Eriksson, E.M.Y.; Chin, R.; Li, S.; Wall, D.M.; et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J. Hepatol. 2010, 53, 599–607. [CrossRef] [PubMed]
20. Alvarez-Lajonchere, L.; Shoukry, N.H.; Gra, B.; Amador-Cañizares, Y.; Helle, F.; Bédard, N.; Guerra, I.; Drouin, C.; Dubuisson, J.; González-Horta, E.E.; et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J. Viral Hepat. 2009, 16, 156–167. [CrossRef] [PubMed]
21. Di Bisceglie, A.M.; Janczweska-Kazek, E.; Habersetzer, F.; Mazur, W.; Stanciu, C.; Carreno, V.; Tanasescu, C.; Flisiak, R.; Romero-Gómez, M.; Fich, A.; et al. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic HCV infection. Gastroenterology 2014, 147, 119–131. [CrossRef] [PubMed]
22. Habersetzer, F.; Honnet, G.; Bain, C.; Maynard Muet, M.; Leroy, V.; Zarski, J.P.; Feray, C.; Baumert, T.F.; Bronowicki, J.P.; Doffoël, M.; et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 2011, 141, 890–899. [CrossRef] [PubMed]
23. Barnes, E.; Folgori, A.; Capone, S.; Swadling, L.; Aston, S.; Kurioka, A.; Meyer, J.; Huddart, R.; Smith, K.; Townsend, R.; et al. Novel adenovirus-based vaccines induce broad and sustained T-cell responses to HCV in man. Sci. Transl. Med. 2012. [CrossRef] [PubMed]
24. Kelly, C.; Swadling, L.; Capone, S.; Brown, A.; Richardson, R.; Halliday, J.; von Delft, A.; Oo, Y.; Mutimer, D.; Kurioka, A.; et al. Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans. Hepatology 2015, 63, 1455–1470. [CrossRef] [PubMed]
25. Swadling, L.; Capone, S.; Antrobus, R.D.; Brown, A.; Richardson, R.; Newell, E.W.; Halliday, J.; Kelly, C.; Bowen, D.; Fergusson, J.; et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T-cell memory. Sci. Transl. Med. 2014. [CrossRef] [PubMed]
26. Wherry, E.J.; Blattman, J.N.; Ahmed, R. Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J. Virol. 2005, 79, 8960–8968. [CrossRef] [PubMed]
27. Klenerman, P.; Hill, A. T cells and viral persistence: Lessons from diverse infections. Nat. Immunol. 2005, 6, 873–879. [CrossRef] [PubMed]
28. Sheehy, S.H.; Duncan, C.J.A.; Elias, S.C.; Choudhary, P.; Biswas, S.; Halstead, F.D.; Collins, K.A.; Edwards, N.J.; Douglas, A.D.; Anagnostou, N.A.; et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 2012, 20, 2355–2368. [CrossRef] [PubMed]
29. Porter, D.W.; Thompson, F.M.; Berthoud, T.K.; Hutchings, C.L.; Andrews, L.; Biswas, S.; Poulton, I.; Prieur, E.; Correa, S.; Rowland, R.; et al. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 2011, 29, 7514–7522. [CrossRef] [PubMed]
30. Folgori, A.; Capone, S.; Ruggeri, L.; Meola, A.; Sporeno, E.; Ercole, B.B.; Pezzanera, M.; Tafi, R.; Arcuri, M.; Fattori, E.; et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 2006, 12, 190–197. [CrossRef] [PubMed]
31. Colloca, S.; Barnes, E.; Folgori, A.; Ammendola, V.; Capone, S.; Cirillo, A.; Siani, L.; Naddeo, M.; Grazioli, F.; Esposito, M.L.; et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 2012. [CrossRef] [PubMed]
32. Batty, E.M.; Wong, T.H.N.; Trebes, A.; Argoud, K.; Attar, M.; Buck, D.; Ip, C.L.C.; Golubchik, T.; Cule, M.; Bowden, R.; et al. A modified RNA-Seq approach for whole genome sequencing of RNA viruses from faecal and blood samples. PLoS ONE 2013. [CrossRef] [PubMed]
33. Lamble, S.; Batty, E.; Attar, M.; Buck, D.; Bowden, R.; Lunter, G.; Crook, D.; El-Fahmawi, B.; Piazza, P. Improved workflows for high throughput library preparation using the transposome-based Nextera system. BMC Biotechnol. 2013. [CrossRef] [PubMed]
34. Gaidatzis, D.; Lerch, A.; Hahne, F.; Stadler, M.B. QuasR: Quantification and annotation of short reads in R. Bioinformatics 2015, 31, 1130–1132. [CrossRef] [PubMed]
35. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011. [CrossRef]
36. Langmead, B.; Salzberg, S.L. Fast gapped-read alignment with Bowtie2. Nat. Methods 2012, 9, 357–359. [CrossRef] [PubMed]
37. Smith, D.B.; Bukh, J.; Kuiken, C.; Muerhoff, A.S.; Rice, C.M.; Stapleton, J.T.; Simmonds, P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 2014, 59, 318–327. [CrossRef] [PubMed]
38. Yang, X.; Charlebois, P.; Gnerre, S.; Coole, M.G.; Lennon, N.J.; Levin, J.Z.; Qu, J.; Ryan, E.M.; Zody, M.C.; Henn, M.R. De novo assembly of highly diverse viral populations. BMC Genom. 2012. [CrossRef] [PubMed]
39. Lee, W.P.; Stromberg, M.P.; Ward, A.; Stewart, C.; Garrison, E.P.; Marth, G.T. MOSAIK: A hash-based algorithm for accurate next-generation sequencing short-read mapping. PLoS ONE 2014. [CrossRef] [PubMed]
40. Yang, X.; Charlebois, P.; Macalalad, A.; Henn, M.R.; Zody, M.C. V-Phaser 2: Variant inference for viral populations. BMC Genom. 2013. [CrossRef] [PubMed]
41. Henn, M.R.; Boutwell, C.L.; Charlebois, P.; Lennon, N.J.; Power, K.A.; Macalalad, A.R.; Berlin, A.M.; Malboeuf, C.M.; Ryan, E.M.; Gnerre, S.; et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 2012. [CrossRef] [PubMed]
42. Aste-Amézaga, M.; Bett, A.J.; Wang, F.; Casimiro, D.R.; Antonello, J.M.; Patel, D.K.; Dell, E.C.; Franlin, L.L.; Dougherty, N.M.; Bennett, P.S.; et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: Application in epidemiologic studies and in the design of adenovector vaccines. Hum. Gene Ther. 2004, 15, 293–304. [CrossRef] [PubMed]
43. Hakamada, T.; Funatsuki, K.; Morita, H.; Ugajin, T.; Nakamura, I.; Ishiko, H.; Matsuzaki, Y.; Tanaka, N.; Imawari, M. Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human leukocyte antigen-A*2402-binding motifs. J. Gen. Virol. 2004, 85, 1521–1531. [CrossRef] [PubMed]
44. Guo, Z.; Zhang, H.; Rao, H.; Jiang, D.; Cong, X.; Feng, B.; Wang, J.; Wei, L.; Chen, H. DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response. PLoS ONE 2012. [CrossRef]
45. Barnes, E.; Gelderblom, H.C.; Humphreys, I.; Semmo, N.; Reesink, H.W.; Beld, M.G.; van Lier, R.A.; Klenerman, P. Cellular Immune Responses during High-Dose Interferon-_ Induction Therapy for Hepatitis C Virus Infection. J. Infect. Dis. 2009, 199, 819–828. [CrossRef] [PubMed]
46. Kuntzen, T.; Timm, J.; Berical, A.; Lewis-Ximenez, L.L.; Jones, A.; Nolan, B.; Schulze zur Wiesch, J.; Li, B.; Schneidewind, A.; Kim, A.Y.; et al. Viral sequence evolution in acute hepatitis C virus infection. J. Virol. 2007, 81, 11658–11668. [CrossRef] [PubMed]
47. Timm, J.; Lauer, G.M.; Kavanagh, D.G.; Sheridan, I.; Kim, A.Y.; Lucas, M.; Pillay, T.; Ouchi, K.; Reyor, L.L.; zur Wiesch, J.S.; et al. CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med. 2004, 200, 1593–1604. [CrossRef] [PubMed]
48. Bengsch, B.; Seigel, B.; Ruhl, M.; Timm, J.; Kuntz, M.; Blum, H.E.; Pircher, H.; Thimme, R. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T-cells is linked to antigen recognition and T-cell differentiation. PLoS Pathog. 2010, 6, e1000947. [CrossRef] [PubMed]
49. Bolinger, B.; Sims, S.; Swadling, L.; O’Hara, G.; de Lara, C.; Baban, D.; Saghal, N.; Lee, L.N.; Marchi, E.; Davis, M.; et al. Adenoviral vector vaccination induces a conserved program of CD8(+) T-cell memory differentiation in mouse and man. Cell Rep. 2015, 13, 1578–1588. [CrossRef] [PubMed]
50. Alanio, C.; Nicoli, F.; Sultanik, P.; Flecken, T.; Perot, B.; Duffy, D.; Bianchi, E.; Lim, A.; Clave, E.; van Buuren, M.M.; et al. Bystander hyperactivation of preimmune CD8(+) T-cells in chronic HCV patients. Elife 2015. [CrossRef] [PubMed]
51. Swadling, L.; Nuffield Department of Medicine, University of Oxford, Oxford, UK. Unpublished data. 2016.
52. Callendret, B.; Eccleston, H.B.; Satterfield, W.; Capone, S.; Folgori, A.; Cortese, R.; Nicosia, A.; Walker, C.M. Persistent HCV replication despite priming of functional CD8+ T-cells by combined therapy with a vaccine and direct acting antiviral. Hepatology 2015. [CrossRef]
53. Rizza, P.; Capone, I.; Moretti, F.; Proietti, E.; Belardelli, F. IFN-α as a vaccine adjuvant: Recent insights into the mechanisms and perspectives for its clinical use. Expert Rev. Vaccines 2011, 10, 487–498. [CrossRef] [PubMed]
54. Penna, A.; Pilli, M.; Zerbini, A.; Orlandini, A.; Mezzadri, S.; Sacchelli, L.; Missale, G.; Ferrari, C. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007, 45, 588–601. [CrossRef] [PubMed]
55. Wherry, E.J. T cell exhaustion. Nat. Immunol. 2011, 12, 492–499. [CrossRef] [PubMed]
56. Doering, T.A.; Crawford, A.; Angelosanto, J.M.; Paley, M.A.; Ziegler, C.G.; Wherry, E.J. Network analysis reveals centrally connected genes and pathways involved in CD8(+) T-cell exhaustion versus memory. Immunity 2012, 37, 1130–1144. [CrossRef] [PubMed]
57. Rao, R.R.; Li, Q.; Odunsi, K.; Shrikant, P.A. The mTOR kinase determines effector versus memory CD8+ T-cell fate by regulating the expression of transcription factors T-bet and eomesodermin. Immunity 2010, 32, 67–78. [CrossRef] [PubMed]
58. Banerjee, A.; Gordon, S.M.; Intlekofer, A.M.; Paley, M.A.; Mooney, E.C.; Lindsten, T.; Wherry, E.J.; Reiner, S.L. Cutting edge: The transcription factor eomesodermin enables CD8+ T-cells to compete for the memory cell niche. J. Immunol. 2010, 185, 4988–4992. [CrossRef] [PubMed]
59. Paley, M.A.; Kroy, D.C.; Odorizzi, P.M.; Johnnidis, J.B.; Dolfi, D.V.; Barnett, B.E.; Bikoff, E.K.; Robertson, E.J.; Lauer, G.M.; Reiner, S.L.; Wherry, E.J. Progenitor and terminal subsets of CD8+ T-cells cooperate to contain chronic viral infection. Science 2012, 338, 1220–1225. [CrossRef] [PubMed]
60. Kurktschiev, P.D.; Raziorrouh, B.; Schraut, W.; Backmund, M.; Wächtler, M.; Wendtner, C.-M.; Bengsch, B.; Thimme, R.; Denk, G.; Zachoval, R.; et al. Dysfunctional CD8+ T-cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J. Exp. Med. 2014, 211, 2047–2059. [CrossRef] [PubMed]
61. Fuller, M.J.; Shoukry, N.H.; Gushima, T.; Bowen, D.G.; Callendret, B.; Campbell, K.J.; Hasselschwert, D.L.; Hughes, A.L.; Walker, C.M. Selection-driven immune escape is not a significant factor in the failure of CD4 T-cell responses in persistent hepatitis C virus infection. Hepatology 2010, 51, 378–387. [CrossRef] [PubMed]
62. Puig, M.; Mihalik, K.; Tilton, J.C.; Williams, O.; Merchlinsky, M.; Connors, M.; Feinstone, S.M.; Major, M.E. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 2006, 44, 736–745. [CrossRef] [PubMed]
63. Kanagavelu, S.; Termini, J.M.; Gupta, S.; Raffa, F.N.; Fuller, K.A.; Rivas, Y.; Philip, S.; Kornbluth, R.S.; Stone, G.W. HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T-cell mediated anti-viral immunity. PLoS ONE 2014, 9, e90100. [CrossRef] [PubMed]
64. Ragonnaud, E.; Andersson, A.-M.C.; Pedersen, A.E.; Laursen, H.; Holst, P.J. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression. Vaccine 2016, 34, 2147–2156. [CrossRef] [PubMed]
65. Gardiner, D.; Lalezari, J.; Lawitz, E.; DiMicco, M.; Ghalib, R.; Reddy, K.R.; Chang, K.M.; Sulkowski, M.; Marro, S.O.; Anderson, J.; et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE 2013, 8, e63818. [CrossRef] [PubMed]
66. Fuller, M.J.; Callendret, B.; Zhu, B.; Freeman, G.J.; Hasselschwert, D.L.; Satterfield, W.; Sharpe, A.H.; Dustin, L.B.; Rice, C.M.; Grakoui, A.; et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc. Natl. Acad. Sci. USA 2013, 110, 15001–15006. [CrossRef] [PubMed]
67. Nakamoto, N.; Kaplan, D.E.; Coleclough, J.; Li, Y.; Valiga, M.E.; Kaminski, M.; Shaked, A.; Olthoff, K.; Gostick, E.; Price, D.A.; et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008, 134, 1927–1937. [CrossRef] [PubMed]
68. Penaloza-MacMaster, P.; Provine, N.M.; Blass, E.; Barouch, D.H. CD4 T cell depletion substantially augments the rescue potential of PD-L1 blockade for deeply exhausted CD8 T cells. J. Immunol. 2015, 195, 1054–1063. [CrossRef] [PubMed]